Sagar Lonial, MD, of Emory University School of Medicine, summarizes his educational session on this vital topic.
Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology.
Stephen J. Schuster, MD, of the University of Pennsylvania, discusses the findings of a study of chimeric antigen receptor modified T cells directed against CD19 in patients with relapsed or refractory disease (Abstract 183).
Alok A. Khorana, MD, of the Cleveland Clinic, discusses study results on the use of dalteparin for thromboprophylaxis in cancer patients at high risk for the condition (Abstract 427).
Nathan Hale Fowler, MD, of MD Anderson Cancer Center, discusses a multicenter trial in which ibrutinib plus rituximab was administered to treatment-naive patients with follicular lymphoma (Abstract 470).
David Henry, MD, of Pennsylvania Hospital, discusses the exciting developments in multiple myeloma treatment, including the three new drugs approved for the disease in November 2015.
